Latest news on Alzheimer's

The European Researchers’ Night is held every year on the last Friday of September in more than 300 cities across 30 European countries

Following the positive opinion from the EMA in July, the European Commission has now authorized the marketing of the drug.

The international study shows that this biomarker allows detection of the presence of amyloid beta deposits, a key pathology in the development of the disease, in individuals without cognitive impairment

This year the Foundation highlights the role of the caregiver, warn about the lack of institutional support and emphasise research as the only way to find a solution to the disease

A clinical trial conducted jointly by the Research Institute of Hospital del Mar and the Barcelonaβeta Brain Research Center, concludes that combining a healthy lifestyle program with epigallocatechin gallate (EGCG), a natural compound found in green tea, could offer sustained cognitive benefits in people at high risk of developing Alzheimer’s dise

The drug was approved following a review of new data submitted by the pharmaceutical company after an initial negative opinion in March of this year.

This research achieved a more precise measurement of sleep quality thanks to the combined use of actigraphy, brain MRI scans, and biomarker analysis.

Her work focused on understanding how telomere length—a key marker of biological aging—influences brain vulnerability and the development of Alzheimer’s disease.

Our researchers will present 7 talks and 22 scientific posters during the 5 days of the congress